Pregnancy Cat

The safety of epalrestat in pregnant women has not been established. The drug may be used in pregnant women or in women who may possibly be pregnant only if expected therapeutic benefits outweigh the possible risks associated with the treatment. Breast-feeding should be avoided during administration of epalrestat.

Precautions

The administration of Epalrestat should be considered to patients showing high glycohemoglobin values even after fundamental therapies for diabetes mellitus such as diet therapy, exercise therapy and treatment with an oral hypoglycemic agent, insulin etc. The efficacy of this product has not been established in patients with diabetic peripheral neuropathy with irreversible organic changes. The patient should be carefully monitored during the administration of this product. When the efficacy of this product is not observed even after 12 weeks of administration, other appropriate therapies should be taken.

Overdose Effects

n/a

Drug Classes

Aldose reductase inhibitor

Storage Conditions

Do not store above 30°C temperature. Keep away from light and wet place. Keep out of reach of children.

Composition

n/a

Mode Of Action

Epalrestat specifically inhibits aldose reductase and accumulation of sorbitol in the nerve; thereby improves subjective symptoms and nerve dysfunction in patients with diabetic peripheral neuropathy.

Reconstitution

n/a